[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

TCR Engineered T-Cell Therapy 2018: an industry analysis of technologies, pipelines, stakeholders & deals

May 2018 | 294 pages | ID: TDCB4EA590DEN
La Merie Publishing

US$ 2,538.00

E-mail Delivery (PDF)

Download PDF Leaflet

Wire Transfer
Checkout Later
Need Help? Ask a Question
T-Cell Receptors (TCR) and Chimeric Antigen Receptors (CAR) are the cutting edge of adoptive T-cell therapy. Both receptors deploy T-cells to target the tumor, but CAR T-cells (CAR-T) are limited to binding to cell surface antigens, while TCR T-cells (TCR-T) recognize peptides (derived from intracellular proteins) presented on the cell surface by the major histocompatibility complex (MHC) class I.

TCR-Ts have so far operated in the shadow of CAR-Ts, but may have the advantage in solid tumors. The first approved CD19-specific CAR-Ts are indicated for hematologic malignancies, but CAR-Ts were less successful against solid tumors.

This report „TCR Engineered T-Cell Therapy 2018: an industry analysis of technologies, pipelines, stakeholders & deals“ published in May 2018 brings you up-to-date regarding key TCR-T players, key TCR-T technologies and product candidates, business models, deals and funding opportunities. The report analyzes the TCR-T pipelines and stakeholders in the field, especially focused and diversified TCR-T companies and their relationship with academia and major pharma/biotech. The report highlights the value of TCR-T assets in terms of partnering economic conditions, acquisition prices and financing rounds.

Download Sample Pages: TCR Engineered T-Cell Therapy 2018: an industry analysis of technologies, pipelines, stakeholders & deals

This report has been prepared by use of in-house databases and desktop search to identify and describe company, product, technology and business/financing profiles which then were evaluated and analyzed with a final outlook describing perspectives with challenges and opportunities. Sources of information are provided by scientific and non-scientific references, e.g. press releases, stock exchange disclosures, presentations, annual reports, fact sheets and patent applications (with hyperlinks leading to the source of information).

Key questions answered:
  • Which targets are chosen for developmen of TCR-Ts?
  • How close are neoantigen-specific TCR-Ts to the clinic?
  • Which technologies are used for generation of T-Cell Receptors?
  • Has clinical proof-of-concept been shown for any TCR-T?
  • How does the TCR-T pipeline look like?
  • What manufacturing strategies and solutions have companies chosen?
  • Are next generation TCR-Ts already in development?
  • What are the key technologies for a successful TCR-T?
  • Who are the key players in the TCR-T field?
  • How tough is competition among TCR-T developers?
  • Should companies be focused on TCR-Ts only or be diversified into various adoptive T-cell therapeutics?
  • Which technologies and assets attract licensees?
  • How is the financing situation for TCR-T?
  • What are the key success factors for TCR-Ts?
Target audience:
  • Leading Pharmaceutical companies
  • Suppliers
  • Contractors
  • Technologists
  • R&D staff
  • Consultants
  • Analyst
  • CSO's
  • CEO’s
  • CIO’s
  • COO’s
  • Business development managers
  • Investors
  • Governments
  • Agencies
  • Industry organisations
  • Banks



3.1 Overview & Discussion
  3.1.1 Technologies for Discovery of Antigens for TCRs
  3.1.2 Technologies for Discovery of TCRs
  3.1.3 Allogeneic T-Cell Technologies
  3.1.4 Technologies for Next Generation TCR T-Cells
3.2 Technologies for Discovery of Targets for TCRs
  3.2.2 Target Selection for SPEAR T-Cells
  3.2.3 Phosphopeptide Library
  3.2.4 HTS Platform for Neoantigen Identification
  3.2.5 pMHC Target Discovery
  3.2.6 EpiTarget Platform
  3.2.7 Neoantigen Prediction
3.3 Technologies for TCR Discovery
  3.3.1 SPEAR T-Cell Technology
  3.3.2 High-Throughput Identification of TUMAP-Restriced TCRs & ActEngine
  3.3.3 Single Cell Sequencing Platform
  3.3.4 TCR-GENErator
  3.3.5 HTS TCR Discovery and Sleeping-Beauty Expression System
  3.3.6 Natural, High Affinity TCRs (Bellicum)
  3.3.7 High-throughput cloning and characterisation of naturally selected TCRs
  3.3.8 Natural TCR Library
  3.3.9 Natural TCRs from Vaccinated Patients
  3.3.10 T-Rx Mammalian TCR Display
  3.3.11 VelociT for T-Cell Receptor Discovery
  3.3.12 Combinatorial TCR Exchange (CTE)
  3.3.13 Immune Repertoire Capture
  3.3.14 E-ALPHA Phage Display
  3.3.15 TCRL Antibodies
  3.3.16 ACTolog
  3.3.17 NEO-STIM
3.4 TCR Engineered Allogeneic T-Cells
  3.4.1 ACTallo
  3.4.2 universal Immune Cell Therapies (uICT)
  3.4.3 GammaDelta T-Cells
  3.4.4 Universal Donor Stem Cells
  3.4.5 ATO Allogeneic T-Cells
3.5 Next Generation Technologies to Improve Safety & Efficacy
  3.5.1 ARTEMIS Technology
  3.5.2 CID Technology Platform
  3.5.3 Custom Cell Engineering Technologies synNotch and Throttle
  3.5.4 DEACT Technology
  3.5.5 Dominant TCR Technology
  3.5.6 RetroNectin and siTCR Vector Technologies
  3.5.7 Stem-to-T-Cell Technology
  3.5.8 Transmembrane Immunomodulatory Protein (TIP) Technology


4.1 Overview & Discussion
  4.1.1 Proof-of-concept
  4.1.2 Target Selection
  4.1.3 T-Cell Sources & Subtypes
  4.1.4 Use of Switches & Next Generation Constructs
4.2 Profiles of MAGE-A Specific TCR T-Cells
  4.2.1 KITE-718
  4.2.2 MAGE-A4c1032 T
  4.2.3 MAGE-A10c796 T
  4.2.4 TBI-1201
4.3 Profiles of NY-ESO-1 Specific TCR T-Cells
  4.3.1 GSK3377794
  4.3.2 NYCE T Cells
  4.3.3 TBI-1301
4.4 Profiles of AFP Specific TCR T-Cells
  4.4.1 AFPc332 T
  4.4.2 ET1402L1 CAR T-Cells
4.5 Profiles of PRAME Specific TCR T-Cells
  4.5.1 BPX-701
  4.5.2 MDG1011
  4.5.3 Dual Switch PRAME TCR T-Cells
4.6 Profiles of WT1 Specitic TCR T-Cells
  4.6.1 CMD-602
  4.6.2 JTCR016
  4.6.3 WT1-Specific Transgenic T-Cells
4.7 Profiles of Other Target Specific TCR T-Cells
  4.7.1 IMA201
  4.7.2 KITE-439
  4.7.3 LTC-H1
  4.7.4 TC-210
  4.7.5 ZI-H04
  4.7.6 ZI-T01
4.8 Profiles of Neoantigen Specific TCR T-Cells
  4.8.1 IMA101
  4.8.2 NEO-PTC-01



6.1 Company Overview & Discussion
  6.1.1 Pure Play TCR T-Cell Companies
  6.1.2 Diversified Companies with TCR-T Activities
6.2 Pure Play TCR T-Cell Companies
  6.2.1 Adaptimmune Therapeutics
  6.2.2 Gadeta
  6.2.3 Immatics US
  6.2.4 Lion TCR
  6.2.5 Tactiva Therapeutics
  6.2.6 Zelluna Immunotherapies
  6.2.7 TCR2 Therapeutics
6.3 Profiles of Diversified Companies with TCR-T Activities
  6.3.1 Adicet Bio
  6.3.2 AgenTus Therapeutics
  6.3.3 Bellicum Pharmaceuticals
  6.3.4 BioNTech
  6.3.5 Bluebird bio
  6.3.6 Cell Medica
  6.3.7 Eureka Therapeutics
  6.3.8 GlaxoSmithKline
  6.3.9 Intellia Therapeutics
  6.3.10 Juno, a Celgene Company
  6.3.11 Kite, a Gilead Company
  6.3.12 Medigene
  6.3.13 Neon Therapeutics
  6.3.14 Regeneron Pharmaceuticals
  6.3.15 Takara Bio
  6.3.16 TC BioPharm
  6.3.17 Tmunity Therapeutics
  6.3.18 ZIOPHARM Oncology
6.4 Other Companies with TCR-T Activities
  6.4.1 Alpine Immune Sciences
  6.4.2 Atreca
  6.4.3 ImmunoCellular Therapeutics


7.1 Role of academia for the TCR-T industry
7.2 Role of Big Pharma & Biotech for TCR-T
7.3 Technology In-Licensing Deals
7.4 Collaborative Arrangements
7.5 Acquisitions of Companies and Assets
7.6 Financing of TCR-T Companies




Table 1: Overview of Corporate Technologies to Discover pMHC Targets for TCRs
Table 2: Overview of Corporate Technologies to Discover Therapeutic TCRs
Table 3: Overview of Corporate Technologies of TCR-Engineered Allogeneic T-Cells
Table 4: Overview of Corporate Technologies to Improve Safety & Efficacy of TCR T-Cells
Table 5: Overview of TCR T-Cell Constructs in Development
Table 6: Overview of Company Solutions for Manufacturing of Vector & Cells
Table 7: Overview of in-house Company Manufacturing Solutions
Table 8: Overview of Company Choices of CMO
Table 9: Overview of Company Manufacturing Collaborations with Academia/Hospitals
Table 10: Overview of TCR T-Cell Company Profiles
Table 11: Overview of Profiles of Pure Play TCR-T Companies
Table 12: Overview of Profiles of Diversified Companies with TCR-T Activities
Table 13: Adaptimmune’s Pipeline of SPEAR T-Cells
Table 14: TCR T-cell Pipeline of Lion TCR
Table 15: TCR2 Therapeutics’ TRuC-T Cell Pipeline
Table 16: TCR T-Cell Pipeline of Zelluna Immunotherapy
Table 17: Bellicum Pharmaceuticals’ Pipeline
Table 18: Cell Medica’s Pipeline
Table 19: Overview of Kite Pharma’s Access to Technologies with Focus on TCR
Table 20: NCI Programs of TCR T-Cells under CRADA with Kite
Table 21: TC BioPharm’s Pipeline of ?? T-cell programs
Table 22: Clinical Pipeline of Tmunity Therapeutics
Table 23: Technology Spin-Out from Academia
Table 24: Deals with Major Pharma & Biotech
Table 25: Technology In-Licensing from Pharma & Biotech
Table 26: Collaborations & Joint Ventures
Table 27: Acquisitions
Table 28: Financing Sources of Pure Play TCR-T Companies
Table 29: Financing Sources of Selected Diversified Companies with TCR-T Activities

More Publications